Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: Biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method

Expert Opinion on Drug Delivery

Volumn 11, Issue 6, 2014, Pages 827-842

  Md, Shadab ^a   Haque, Shadabul ^a   Fazil, Mohammad ^a   Kumar, Manish ^b   Baboota, Sanjula ^a   Sahni, Jasjeet K ^a   Ali, Javed ^a  

^a HAMDARD UNIVERSITY   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Bromocriptine; Chitosan; Dopamine; Nanoparticles; Nasal retention; Parkinson's disease

Indexed keywords

BROMOCRIPTINE; CHITOSAN; DOPAMINE; HALOPERIDOL; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RETENTION; DRUG STABILITY; DRUG TRANSPORT; FEMALE; GELATION; HISTOPATHOLOGY; MALE; MASS SPECTROMETRY; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; NOSE MUCOSA; NOSE TO BRAIN DRUG DELIVERY SYSTEM; PARKINSON DISEASE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

BROMOCRIPTINE; CHITOSAN; DOPAMINE; NANOPARTICLES; NASAL RETENTION; PARKINSON'S DISEASE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIPARKINSON AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; BROMOCRIPTINE; CHITOSAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG DELIVERY SYSTEMS; FEMALE; MALE; MASS SPECTROMETRY; MICE; NANOPARTICLES; NASAL MUCOSA; PARKINSON DISEASE; RADIOPHARMACEUTICALS; SODIUM PERTECHNETATE TC 99M; TISSUE DISTRIBUTION;

EID: 84901288353     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.894504     Document Type: Article

References (37)

1. Luthra PM, Barodia SK, Raghubir R. Antagonism of haloperidol-induced swim impairment in l-dopa and caffeine treated mice: A pre-clinical model to study Parkinson's disease. J Neurosci Methods 2009;178:284-90
2. Verma R, Nehru B. Effect of centrophenoxine against rotenoneinduced oxidative stress in an animal model of Parkinson's disease. Neurochem Int 2009;55:369-75
3. Muthane UB, Ragothaman M, Gururaj G. Epidemiology of Parkinson's disease and movement disorders in India: Problems and possibilities. J Assoc Physicians India 2007;55:719-24
4. Md S, Haque S, Sahni JK, et al. New non-oral drug delivery systems for Parkinson's disease treatment. Expert Opin Drug Deliv 2011;8(3):359-74
5. Gárdián G, Vécsei L. Medical treatment of Parkinson's disease: Today and the future. Int J Clin Pharmacol Ther 2010;48:633-42
6. Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci 2010;99(4):1654-73
7. Fazil M, Shadab M, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012;47(1):6-15
8. Liu Z, Jiang M, Kang T, et al. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain Delivery of NAP peptide following intranasal administration. Biomaterials 2013;34:3870-81
9. Wen Z, Yan Z, Hu K, et al. Odorranalectin-conjugated nanoparticles: Preparation, brain Delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release 2011;151:131-8
10. Vila A, Sanchez A, Tobio M, et al. Design of biodegradable particles for protein Delivery. J Control Release 2002;78:15-24 (Pubitemid 34081849
11. Haque S, Shadab M, Fazil M, et al. Venlafaxine loaded chitosan NPs for brain targeting, pharmacokinetic and pharmacodynamic evaluation. Carbohydr Polym 2012;89(1):72-9
12. Ieva E, Trapani A, Cioffi N, et al. Analytical characterization of chitosan nanoparticles for peptide drug delivery applications. Anal Bioanal Chem 2009;393:207-15 (Pubitemid 50316506
13. Luo Y, Zhang B, Whent M, et al. Preparation and characterization of zein/ chitosan complex for encapsulation of tocopherol, and its in vitro controlled release study. Colloids Surf B Biointerfaces 2011;85:145-52
14. Lim JH, Kim SS, Boo DH, et al. Protective effect of bromocriptine against BH4-induced Cath. A cell death involving up-regulation of antioxidant enzymes. Neurosci Lett 2009;451(3):185-9
15. Md S, Khan RA, Mustafa G, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain Delivery: Pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci 2013;48(3):393-05
16. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: An update. Clin Pharmacokinet 2006;45(2):109-36 (Pubitemid 43290827
17. Degim IT, Acartürk F, Erdogan D, Lortlar ND. Transdermal administration of bromocriptine. Biol Pharm Bull 2003;26(4):501-5 (Pubitemid 39663596
18. Choi YJ, Seo MK, Kim IC, Lee YH. High-performance liquid chromatographic assay of bromocriptine in plasma and eye tissue of the rabbit. J Chromatogr B Biomed Sci Appl 1997;694:415-20
19. Valente D, Ezan E, Créminon C, et al. Enzyme immunoassays for bromocriptine and its metabolites. J Immunoassay 1996;17(4):297-20
20. Salvador A, Dubreuil D, Denouel J, Millerioux L. Sensitive method for the quantitative determination of bromocriptine in human plasma by liquid chromatography-Tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;820:237-42 (Pubitemid 40724590
21. Faiyazuddin M, Ahmad N, Khar RK, et al. Stabilized terbutaline submicron Drug aerosol for deep lungs deposition: Drug assay, pulmonokinetics and biodistribution by UHPLC/ESI-q-TOFMS method. Int J Pharm 2012;434:59-69
22. Md S, Kumar M, Baboota S, et al. Preparation, characterization and evaluation of bromocriptine loaded chitosan nanoparticles for intranasal delivery. Sci Adv Mater 2012;4(9):949-60
23. Dudhani AR, Kosaraju SL. Bioadhesive chitosan nanoparticles: Preparation and characterization. Carbohydr Polym 2010;81:243-51
24. Wilson B, Samanta MK, Santhi K, et al. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine 2010;6(1):144-52
25. Khan S, Patil K, Bobade N, et al. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target 2010;18(3):223-34
26. ICH harmonised tripartite guideline. Validation of analytical procedures: Text and methodology Q2(R1). ICH harmonised tripartite guideline 2005 [Last assessed 6 January 2014]
27. ICH harmonised tripartite guideline. Stability testing of New Drug Substances and Products Q1A(R2). ICH harmonised tripartite guideline 2003 [Last assessed 6 January 2014]
28. Kumar M, Misra A, Babbar AK, et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008;358(1-2):285-91
29. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008;70(3):735-40
30. Fenli S, Wang F, Zhu R, Li H. Determination of 5-hydroxytryptamine norepinephrine, dopamine and their metabolites in rat brain tissue by LC-ESI-MS-MS. Chromatographia 2009;69:207-13
31. Trapani A, De Giglio E, Cafagna D, et al. Characterization and evaluation of chitosan nanoparticles for dopamine brain Delivery. Int J Pharm 2011;419:296-07
32. Nageswari A, Reddy KV, Mukkanti K. Stability-indicating UPLC method for determination of Imatinib Mesylate and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. J Pharm Biomed Anal 2012;66:109-15
33. Al-Ghananeem AM, Saeed H, Florence R, et al. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses. J Drug Target 2010;18(5):381-8
34. Zhu Z, Bartol M, Shen K, Johnson SW. Excitatory effects of dopamine on subthalamic nucleus neurons: In vitro study of rats pretreated with 6-hydroxydopamine and levodopa. Brain Res 2002;945:31-40 (Pubitemid 34756574
35. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-6
36. Morris GA, Castile J, Smith A, et al. The effect of prolonged storage at different temperatures on the particle size distribution of tripolyphosphate (TPP)-chitosan nanoparticles. Carbohydr Polym 2011;84:1430-4
37. Tsai YM, Chien CF, Lin LC, Tsai TH. Curcumin and its nano-formulation: The kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm 2011;416:331-8